Methyl ether of 1-phenyloxycarbonyl-1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime | 121750-63-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methyl ether of 1-phenyloxycarbonyl-1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime
• 英文别名: phenyl 5-(methoxyiminomethyl)-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 121750-63-8
• 化学式: C₁₄H₁₆N₂O₃
• 分子量: 260.293
• InChiKey: GGIGXOXHMJUBPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  51.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-ethyl-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-methyloxime 、 氯甲酸苯酯 在 盐酸 作用下， 以 1,1-二氯乙烷 、 水 为溶剂， 生成 Methyl ether of 1-phenyloxycarbonyl-1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime
  参考文献：
  名称：

  Carbamate derivatives of the oxime of

  摘要：

  用于治疗患有老年性痴呆症、阿尔茨海默病或记忆缺陷的化合物，其化学式为##STR1##其中R'代表氢，线性、支链或环烷基、烯基或炔基，含有最多8个碳原子，而R代表线性、支链或环烷基、烯基或炔基，含有最多18个碳原子，可能被取代，芳基含有最多14个碳原子，可能被取代，芳基烷基含有最多18个碳原子，可能被取代，以及它们与有机或无机酸形成的盐。

  公开号：

  US04921868A1

文献信息

• Carbamate derivatives of the oxime of
  申请人：Roussel Uclaf

  公开号：US04921868A1

  公开（公告）日：1990-05-01

  Compounds useful in the treatment of patients suffering from senile dementia, Alzheimer's disease, or memory defects, of the formula ##STR1## in which R' represents hydrogen, a linear, branched or cyclic alkyl, alkenyl or alkynyl, containing up to 8 carbon atoms, and R represents a linear, branched or cyclic alkyl, alkenyl, or alkynyl, containing up to 18 carbon atoms, possibly substituted, aryl containing up to 14 carbon atoms, possibly substituted, aralkyl containing up to 18 carbon atoms, possibly substituted, as well as their addition salts with organic or mineral acids.

  用于治疗患有老年性痴呆症、阿尔茨海默病或记忆缺陷的化合物，其化学式为##STR1##其中R'代表氢，线性、支链或环烷基、烯基或炔基，含有最多8个碳原子，而R代表线性、支链或环烷基、烯基或炔基，含有最多18个碳原子，可能被取代，芳基含有最多14个碳原子，可能被取代，芳基烷基含有最多18个碳原子，可能被取代，以及它们与有机或无机酸形成的盐。
• 1-substituted-1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-alkyloximes as novel orally active and long-lasting muscarinic cholinergic agonists
  作者：E Toja、C Bonetti、A Butti、P Hunt、M Fortin、F Barzaghi、ML Formento、A Maggioni、A Nencioni、G Galliani

  DOI：10.1016/0223-5234(92)90186-5

  日期：1992.8

  Our previous attempts to design muscarinic agonists related to arecoline with the prerequisites for clinical use were successful with the discovery of 1,2,5,6-tetrahydropyridine-3-carboxaldehyde-O-methyloxime hydrochloride, RU 35963, and structurally related compounds, in which die metabolically labile ester group of arecoline was replaced with the bioisosteric and stable aldoxime group. With the aim of obtaining compounds with improved cholinomimetic properties, several aryl- and alkyl-carbamates of RU 35963, as well as O-alkyl-, and O-aryl-carbamates of the 1-hydroxy-1,2,5,6-tetrahydropyridine-3- carboxaldehyde-O-methyloxime hydrochloride, 24, have been synthesized and evaluated biologically. The most interesting molecules to emerge from the primary screening have been evaluated more extensively and their cholinomimetic profiles compared with those of the parent molecules. In vitro studies indicate that none of these prodrugs have affinity for muscarinic receptor sites and some of them (aryl-carbamates) have cholinesterase inhibiting properties. Results from in vivo experiments in mice and rats showed that these new substances, 1-[4-chlorophenyl] oxycarbonyl-1,2,5,6-tetrahydropyridine-3- carboxaldehyde-O-methyloxime (16 = RU 47213) in particular, have cholinomimetic properties that compare favourably with those of the parent compounds. After oral administration 16 was clearly superior to RU 35963 in terms of central selectivity, duration of action and therapeutic indexes.